Entera Bio Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENTX research report →
Range $9 – $9
Price Chart
About the company
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures.
- CEO
- Miranda J. Toledano
- IPO
- 2018
- Employees
- 27
- HQ
- Jerusalem, JM, IL
Get TickerSpark's AI analysis on ENTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $575.53M
- P/E
- -8.50
- PEG
- 0.19
- P/S
- 0.00
- P/B
- 1.75
- EV/EBITDA
- -16.93
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.55%
- ROIC
- -6.69%
Latest fiscal year · YoY change
- Revenue
- $42.00K-76.8%
- Gross Profit
- $0-100.0%
- Op Income
- $-11,529,000
- Net Income
- $-11,439,000-19.9%
- EPS
- $-0.25+0.0%
- OCF Growth
- -8.1%
- FCF Growth
- -9.6%
- 52W High
- $4.20
- 52W Low
- $0.91
- 50D MA
- $2.93
- 200D MA
- $2.03
- Beta
- 1.46
- RSI (14)
- 61
- Avg Volume
- 438.35K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Entera Bio said EB613 is advancing toward Phase III, while a market study and new IP filings reinforced the company’s push to position it as an oral anabolic osteoporosis therapy and to seek a global partner.· May 17, 2022
- EB613 is moving toward Phase III, with management saying it is in finalizing registrational study plans and in dialogue with the FDA.
- A market/analytics study found osteoporosis affects over 15 million U.S. patients and that approximately 75% of the target population is not receiving pharmacologic treatment.
- Management said prescribers and payers were receptive to EB613’s oral anabolic profile, and some payers may not require a step edit in this population.
- Entera filed multiple new U.S. patent applications during the quarter to broaden protection around its oral delivery platform and new formulations.
- The company said it is actively pursuing global and regional partnering discussions and expects to try to have something finished by year-end.
The transcript did not include reported revenue, EPS, gross margin, cash balance, or year-over-year financial metrics, and no numeric quarterly operating results were stated on the call. Management’s main forward-looking update was that EB613 is progressing toward Phase III, with registrational study plans being finalized and FDA discussions ongoing. The company also said it expects to be finishing a global partnership transaction by the end of the year, though no timing or financial terms were given.
Spiros Jamas emphasized that the call was brief because the company had already circulated its earnings release, and he framed the quarter around operational progress rather than financial results. He highlighted the addition of Miranda Toledano to the leadership team and said her strategic and Wall Street experience fits Entera’s push toward global partnership discussions and ongoing platform development. His tone was upbeat and focused on execution, IP expansion, and partnering.
Miranda Toledano, now serving as Chief Business Officer, CFO and Head of Strategy, said EB613 has compelling Phase II efficacy and safety data and strong differentiation from its oral route, safety profile and long-validated mechanism of action. She said Entera is laser-focused on finalizing registrational study plans and FDA dialogue, and that the company expects to share more on the Phase III strategy and pipeline over time. No cash, burn, margin, or capital-allocation figures were provided in her remarks.
Analyst questions centered on how much prescriber uptake might occur before bisphosphonates, how far along Asia and other regional partnering discussions are, what exactly is being optimized in the oral delivery platform, and whether EB613 could eventually be studied in other patient groups. Management said payers and prescribers see potential for an oral PTH to move up the treatment chain and may not require a step edit, and it said the company has collected detailed qualitative and quantitative study data that it plans to share in portions over the coming months. On partnering, management said it is pursuing global deals with Torreya’s help and hopes to have something completed by year-end.
The bullish case is that Entera believes EB613’s oral anabolic profile could unlock a much larger osteoporosis market where most patients are untreated and many doctors and payers see room for a better option than injectable PTH agents. Management also said the oral delivery platform is improving bioavailability and lowering variability, while new patents could extend protection and broaden the platform’s utility.
The main risks are that EB613 is still in pre-Phase III planning, so the program remains dependent on FDA alignment, successful trial design, and later clinical execution. The company also has no disclosed financial metrics on the call, and its partnering timeline is uncertain even though management hopes to complete a deal by year-end.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.6%
- Shares Outstanding
- 174.14M
- Float Shares
- 107.29M
of shares held by institutions
28 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bvf Inc/Il | 17.05M | ▲ 14.63M |
| Vivo Capital, LLC | 12.25M | ▲ 12.25M |
| Tcg Crossover Management, LLC | 12.25M | ▲ 12.25M |
| Spruce Street Capital LP | 11.21M | ▲ 11.21M |
| Commodore Capital LP | 7.35M | ▲ 7.35M |
| Seven Fleet Capital Management LP | 6.86M | ▲ 6.67M |
| Siren, L.L.C. | 6.00M | ▲ 5.26M |
| Knoll Capital Management, LLC | 5.83M | ▼ 49.84K |
| Driehaus Capital Management LLC | 5.17M | ▲ 5.17M |
| Venrock Adviser, LLC | 5.11M | ▲ 5.11M |
| Ra Capital Management, L.P. | 4.90M | ▲ 4.90M |
| Logos Global Management LP | 4.41M | ▲ 4.41M |
Held by 3 ETFs
Biggest fund positions in ENTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 18, 26 | Camisasca Riccardo Paolo | other | 0 |
| Aug 7, 26 | Malca Yonatan | other | 22,815 |
| Aug 7, 26 | Taitel Haya | other | 20,790 |
| Aug 7, 26 | Ellis Sean | other | 20,034 |
| Aug 7, 26 | Ellis Sean | other | 40,000 |
| Aug 7, 26 | Yaacov-Garbeli Dana | other | 140,000 |
| Aug 7, 26 | Galitzer Hillel | other | 200,000 |
| Aug 7, 26 | Burshtein Gregory | other | 180,000 |
| Aug 7, 26 | Toledano Miranda Jayne | other | 500,000 |
| Aug 7, 26 | Toledano Miranda Jayne | other | 200,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENTX coverage
Recent articles, reports, and earnings notes.
No research on ENTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENTX report →Head-To-Head Survey: Entera Bio (NASDAQ:ENTX) & Insmed (NASDAQ:INSM)
defenseworld.net · Nov 20
Entera Announces Third Quarter 2026 Financial Results and Business Updates
globenewswire.com · Nov 6
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
globenewswire.com · Oct 27
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
globenewswire.com · Oct 13
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
globenewswire.com · Oct 8
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
globenewswire.com · Oct 6
Correction: Entera to Participate in Upcoming Fall Investor Conferences
globenewswire.com · Aug 27
Entera to Participate in Upcoming Fall Investor Conferences
globenewswire.com · Aug 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.